Otenabant

Otenabant

File:Otenabant.svg

Chemical structure of Otenabant

Otenabant is a pharmaceutical drug that was developed as a cannabinoid receptor antagonist. It was primarily investigated for its potential use in the treatment of obesity and related metabolic disorders. Otenabant acts by blocking the CB1 receptor, which is part of the endocannabinoid system.

Mechanism of Action

Otenabant functions as a selective antagonist of the CB1 receptor, which is predominantly found in the central nervous system and peripheral tissues. By inhibiting the action of endogenous cannabinoids at this receptor, Otenabant reduces appetite and food intake, which can lead to weight loss. The blockade of CB1 receptors also affects lipid metabolism and glucose homeostasis, contributing to its potential benefits in treating metabolic syndrome.

Development and Clinical Trials

Otenabant was developed by Pfizer, a major pharmaceutical company. During its development, Otenabant underwent several clinical trials to assess its efficacy and safety in humans. These trials aimed to determine the drug's impact on body weight, metabolic parameters, and potential side effects.

Side Effects

Like other CB1 receptor antagonists, Otenabant was associated with several side effects. Common adverse effects included nausea, dizziness, and anxiety. More serious concerns were raised about the potential for psychiatric disorders, such as depression and suicidal ideation, which ultimately led to the discontinuation of its development.

Discontinuation

The development of Otenabant was halted due to safety concerns, particularly the risk of psychiatric side effects. This decision was influenced by the withdrawal of similar drugs from the market, such as Rimonabant, which faced similar issues. As a result, Otenabant did not receive regulatory approval and was never marketed.

Related Pages

• Cannabinoid receptor
• Endocannabinoid system
• Obesity
• Metabolic syndrome
• Rimonabant